Observational (n=331)
No
Answers are grounded in this paper and cite their sources.
Objective: The 2018 AHA/ACC cholesterol guidelines recommend considering non-statin agents among very high-risk (VHR) patients with LDL-C ≥ 70 mg/dL after maximizing statin therapy. We aimed to evaluate the prevalence of VHR status in acute myocardial infarction (AMI) patients at hospital discharge and the adherence to guideline-directed cholesterol therapy (GDCT) within one-year follow-up post-AMI. Methods: We performed a retrospective analysis of patients who suffered a type 1 AMI between October 2015 and March 2019, and then were followed at our institution for 1 year after hospital discharge. We calculated the percentage of patients at VHR and among those with follow up lipid panels, we determined the proportion able to achieve GDCT. Results: The mean age of the 331 AMI patients was 61.0 (SD 11.9) years and 33.6% were women. Overall, 268 (81.0%) patients were categorized as having VHR at discharge. Among patients at VHR, a lipid panel was rechecked in 153 individuals (57.1%) within 1 year of discharge, with the median time to lipid recheck being 22.4 weeks (interquartile range: 10.9-40.7 weeks). Among those with a lipid panel re-check, 100 (65.4%) of patients achieved GDCT. Conclusions: Approximately 4 out of 5 AMI patients were considered VHR per the 2018 AHA/ACC guidelines, only about half had follow up lipid panels in the year following AMI, and about two-thirds of those with follow up lipid panels achieved GDCT.
No takes yet. Share an insight, caveat, or question.
Brownstein et al. (2022) conducted an observational in Type 1 acute myocardial infarction (AMI) (n=331). 2018 AHA/ACC very high-risk (VHR) status was evaluated on Prevalence of very high-risk (VHR) status at discharge and achievement of guideline-directed cholesterol therapy (GDCT) among VHR patients with follow-up lipid panels within 1 year. Very high-risk status was present in 81.0% of AMI patients at discharge, with 57.1% having a 1-year lipid recheck and 65.4% of those achieving guideline-directed cholesterol therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: